Drug Type Small molecule drug |
Synonyms 10-[3-(4-methyl-1-piperazinyl)propyl]-2-(trifluoromethyl)-10H-phenothiazine, Trifluoperazine, Trifluoperazine hydrochloride (JAN/USP) + [10] |
Target |
Action antagonists |
Mechanism DRDs antagonists(Dopamine receptors antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date United States (16 Apr 1959), |
Regulation- |
Molecular FormulaC21H26Cl2F3N3S |
InChIKeyBXDAOUXDMHXPDI-UHFFFAOYSA-N |
CAS Registry440-17-5 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D00799 | Trifluoperazine Hydrochloride |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Depressive Disorder | China | 01 Jan 1995 | |
Schizophrenia | China | 01 Jan 1995 | |
Anxiety Disorders | United States | 16 Apr 1959 |
Phase 1/2 | 2 | daurhxbocg = lvpedhgooi tcouicqrdg (fzxpbbgein, ciqktomotq - rlxptbjfks) View more | - | 14 Dec 2022 | |||
Not Applicable | - | - | nbxxkywlku(cmkyunqiyf) = utbhrcpknq jzlsqwlfam (twcemvioht ) | - | 20 May 2012 | ||
(Ionizing radiation) | nbxxkywlku(cmkyunqiyf) = fliholnwbn jzlsqwlfam (twcemvioht ) |